MarcoGerlinger Profile Banner
Marco Gerlinger Profile
Marco Gerlinger

@MarcoGerlinger

Followers
1K
Following
87
Media
28
Statuses
372

Medical Oncologist and Clinician Scientist working on GI Cancer Genomics/Cancer Evolution, Immunotherapies and Biomarkers

London, England
Joined November 2014
Don't wanna be here? Send us removal request.
@MarcoGerlinger
Marco Gerlinger
4 months
🔥Just opened: 4 year CLINICAL LECTURERSHIP position in HISTOPATHOLOGY @NHSBartsHealth and my lab @QMBCI in London: for ST3/4 registrars who already hold a PhD/MD. Great opportunity for a deep dive into the immunobiology of MMRd cancer. Deadline 11/04 10am
0
1
2
@MarcoGerlinger
Marco Gerlinger
5 months
Still time to register for our free @AACR IO webinar today: “Tumour Mutation Burden, Heterogeneity and Immunotherapy Efficacy”with Profs Jaffe, Quezada and Wargo
0
5
6
@MarcoGerlinger
Marco Gerlinger
6 months
Join the discussion: Pervasive Cellular Plasticity intertwined with Darwinian Evolution in Cancer - does this need a new Evolutionary Theory? See our review just out in @trendscancer
Tweet media one
2
16
42
@MarcoGerlinger
Marco Gerlinger
7 months
Touched down in Miami for the 2024 @CCAlliance #CureCRC Summit - very exciting to be here again to help make this cancer history. Well prepared after lovely Christmas dinner and afternoon tea (‼️‼️) on board of the A380 💪💪💪.
0
2
4
@MarcoGerlinger
Marco Gerlinger
9 months
RT @DrHongchengZhu: Starting from International Exchange Award between UK and China supported by @royalsociety, more exciting opportunities….
0
1
0
@MarcoGerlinger
Marco Gerlinger
9 months
RT @BartsGI_Cancer: Kickoff meeting of our new St Barts Hospital - Fudan University Cancer Centre Oesophageal Cancer Research Collaboration….
0
1
0
@MarcoGerlinger
Marco Gerlinger
1 year
Outstanding session with @elena_elez and @BenjcRousseau on immunotherapy biomarkers at @ASCO #ASCO24 this morning. Key messages: Exciting and powerful new IO biomarkers on the horizon. We now need to apply them to large clinical trials including those from industry.
Tweet media one
0
1
12
@MarcoGerlinger
Marco Gerlinger
1 year
Great talk on chromosomal instability by my @QMBCI colleague Dr McClelland @McclellandLab at #AACR24 @AACR in RM29 ongoing
Tweet media one
1
4
26
@MarcoGerlinger
Marco Gerlinger
1 year
RT @YaleCancer: .@politikaterina will be presenting during the Lineage Plasticity in Tumor Evolution and Acquired Resistance educational se….
0
5
0
@MarcoGerlinger
Marco Gerlinger
1 year
RT @CharlesSwanton: What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architectu….
0
163
0
@MarcoGerlinger
Marco Gerlinger
1 year
RT @YaleCancer: .@JeffTownsend discussed how the evolution of #cancer is rarely linear, but a branching model that influences progression #….
0
2
0
@MarcoGerlinger
Marco Gerlinger
1 year
Looking forward to meet for a drink (and science discussion of course…).
0
0
0
@MarcoGerlinger
Marco Gerlinger
1 year
Important POSTER SESSIONS For those of you at #AACR24:.👉🏻Tumor Evolution in Space and Time is on Monday 9am-12:30 (section 12).👉🏻Tumor Evolution Models and Technologies on Tuesday 9am-12:30 (section 13).We received 🏅outstanding 🥇 abstracts this year. Don‘t miss out!!
Tweet media one
0
1
6
@MarcoGerlinger
Marco Gerlinger
2 years
RT @MyriamChalabi: What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess @NatureMedicin….
0
64
0
@MarcoGerlinger
Marco Gerlinger
2 years
RT @QMBCI: We're delighted that Prof Tom Powles (@tompowles1) has been selected as one of @Nature's 10 people who shaped science for his tr….
0
4
0
@MarcoGerlinger
Marco Gerlinger
2 years
It’s a great honour to be part of the @CCAlliance inaugural #CureCRCsummit this week. Brainstorming strategies to cure #colorectal cancer with giants in the field Drs @skopetz, Batlle, Venook, Lenz, @MyriamChalabi, @AndreaCercek + many others
Tweet media one
0
3
9
@MarcoGerlinger
Marco Gerlinger
2 years
RT @BartsGI_Cancer: Important point made in an article in @guardian today: better outcomes for cancer patients who are treated in research….
0
2
0
@MarcoGerlinger
Marco Gerlinger
2 years
-Parallel evolution which surpasses even that in RCC! .-Big headache for biomarker development! .Our study on ITH in dMMR CRCs is out: High mutation supply and strong immune selection pressures make this a great model tumor for #CancerEvo studies.
0
4
21
@MarcoGerlinger
Marco Gerlinger
2 years
RT @BartsGI_Cancer: #ESMO23 congress starts tomorrow. @BartsGI_Cancer consultants @rillepihlak and @MarcoGerlinger will be there and tweet….
0
1
0
@MarcoGerlinger
Marco Gerlinger
2 years
“Understanding immune evasion and suppression in colon cancer liver mets through single cell sequencing” Exciting PhD opportunity in my lab at the Barts Cancer Institute: check details and apply here:
0
9
15